Novel therapy. The last decade has been marked by the clinical trials of eculizumab (ECU) 16, 17, followed in 2007 by the prompt introduction of this agent into standard therapy.ECU is a humanized monoclonal antibody specific for the human plasma complement component C5: by binding to C5, ECU blocks the distal complement pathway and thus protects PNH red cells from complement-mediated lysis..